Targeted look at residual inflammation after a heart attack
Official title: Target Investigation of Residual Inflammation After Non-ST/ ST Elevation Acute Coronary Syndrome - TIRANA (ACS) Prospective REGISTRY
Run by University Hospital Centre Mother Teresa · NCT07026708 · Data updated 2026-11-12
This project will test whether the neutrophil-to-lymphocyte ratio (NLR) from the first routine blood draw can help predict risk of death in adults (18–85) after an acute coronary syndrome treated with PCI.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 1600 (estimated) |
| Sponsor | University Hospital Centre Mother Teresa Academic / other |
| Locations | 1 site (Tirana) |
| Status | Recruiting |
| Started | November 1, 2024 |
| Main results expected | November 1, 2026 |
| Study ends | June 1, 2027 |
| Registry record updated | September 30, 2025 |
| Trial ID | NCT07026708 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–85 admitted with confirmed ACS (STEMI or NSTEMI) who undergo PCI and can be contacted after discharge are the intended participants.
✕Probably not a fit
Patients who die before PCI, those with diagnoses other than ACS or unstable angina, those outside the 18–85 age range, or those without contact information would not be included and are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective observational registry will enroll adults aged 18–85 admitted with confirmed ACS (STEMI or NSTEMI) treated with percutaneous coronary intervention at the University Hospital Centre Mother Teresa in Tirana. NLR will be calculated from the first complete blood count obtained on admission. Patients will be followed for mortality outcomes to see if admission NLR independently predicts death after ACS. The study uses routine laboratory data to explore a low-cost marker for early risk stratification.
Why it matters
Potential benefit: If successful, NLR could become a low-cost, widely available marker to identify patients at higher risk after ACS and guide closer follow-up or targeted treatment.
How similar studies have gone: Previous observational studies have linked higher NLR to worse cardiovascular outcomes, but its independent predictive value for post-ACS mortality in this population has not been firmly established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- All patients (undergoing PCI, aged 18-85 years) presenting to the cardiology department or/and the cardiology intensive care unit with a diagnosis of ACS Exclusion Criteria: * Patients presenting to the cardiology department or/and the cardiology intensive care unit with diagnoses other than ACS and/or UA. Patients who died before undergoing PCI and those who did not provide a contact number.
Where it's running
-
Faculty of Medicine Tirana
Tirana, Albania Recruiting
Study contacts
- Principal investigator: Andi Rroku, MD — Deutsches Herzzentrum der Charité (DHZC) - Campus Benjamin Franklin
- Study coordinator: Martiola Kola, MD
- Email: martiola.kola@gmail.com
- Phone: 003553410998
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Drug-coated balloon treatment during emergency angioplasty for STEMI
This registry will try using drug-coated balloons instead of stents during emergency PCI for people with ST-elevation heart attacks to see how the procedure and patient outcomes compare.
-
Predicting Heart Muscle Recovery After CTO Revascularization
This study looks at whether blood tests and stress echo measurements can predict which patients with CTO will regain heart muscle function after a revascularization procedure.
-
Risk of malignant arrhythmias after acute coronary syndrome
This study tracks how often dangerous heart rhythms occur in adults admitted for ACS and looks for patterns that might predict them.
-
Smartphone AI help for prehospital ECG readings
This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.
-
Optimal timing of staged complete revascularization in STEMI with multivessel disease
This trial tests whether performing staged complete revascularization during the hospital stay or after discharge is best for STEMI patients with multivessel disease.
-
Collagen and omega-3 supplements in middle-aged women
This study tests whether taking collagen and omega-3s together improves joint pain, fatigue, sleep, and overall wellbeing in healthy women aged 35–65 compared with a placebo over 8 weeks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.